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NKG2D is an important activating receptor on lymphocytes.
In human, it interacts with two groups of ligands: the major
histocompatibility complex class I chain-related A/B (MICA/B)
family and the UL-16 binding protein (ULBP) family, also
known as retinoic acid early transcript (RAET1). MIC proteins
are membrane-anchored, but all of the ULBP/RAET1 proteins,
except for RAET1E and RAET1G, are glycosylphosphatidyl-
inositol (GPI)-anchored. To address the reason for these differ-
ences we studied the association of RAET1G with the mem-
brane. Using epitope-tagged RAET1G protein in conjunction
with antibodies to different parts of the molecule and in pulse-
chase experiments, we showed that the C terminus of the pro-
teinwas cleaved soonafter protein synthesis. EndoglycosidaseH
and peptide N-glycosidase treatment and cell surface immuno-
precipitation indicated that most of the protein stayed in the
endoplasmic reticulum, but some of the cleaved form was mod-
ified in the Golgi and transported to the cell surface. We exam-
ined the possibility of GPI anchoring of the protein in three
ways: (i) Phosphatidylinositol (PI)-specific phospholipase C
released the PI-linked form of the protein. (ii) The surface
expression pattern of RAET1G decreased in cells defective in
GPI anchoring through mutant GPI-amidase. (iii) Site-directed
mutagenesis, to disrupt residues predicted to facilitate GPI-an-
choring, resulted in diminished surface expression of RAET1G.
Thus, a form of RAET1G is GPI-anchored, in line with most
other ULBP/RAET1 family proteins. The cytoplasmic tail and
transmembranedomains appear to result fromgeneduplication
and frameshift mutation. Together with our previous results,
our data suggest that RAET1G is regulated post-translationally
to produce a GPI-anchored isoform.
NKG2D3 is a C-type lectin-like activating receptor, ex-
pressed on natural killer (NK) cell and T cells, that plays an
important role in triggering cytotoxic activity. Remarkably, the
receptor interacts with multiple different ligands. In humans,
the ligands fall into two groups, namely theMHC class I chain-
related A/B (MICA/B) family and the UL-16-binding protein
(ULBP) or retinoic acid expressed transcript (RAET1) family
(1–4). In mice, there are at least six NKG2D ligands; some of
which (Rae1-, H60c) are GPI-anchored, and the other three,
H60a, H60b, and Mult1 (murine UL-16-binding protein-like
transcript 1) are transmembrane proteins (5, 6).
MICA/B and ULBP/RAET1 family proteins differ in domain
structure and share low amino acid sequence similarity. Both
MIC family proteins, MICA and MICB, consist of three 
domains, transmembrane domains, and cytoplasmic tail. In
contrast, ULBP/RAET1 proteins have two  domains and, of
the six molecules, four (ULBP1, ULBP2, ULBP3, and ULBP6
(RAET1L)), are GPI-anchored proteins (4, 7). The other two,
ULBP4 (RAET1E) andULBP5 (RAET1G) have been considered
to have transmembrane domains (4, 8).
ULBP/RAET1 family proteins share different degrees of
sequence similarity and may have arisen by a series of gene
duplications (4). SomeULBP/RAET1 loci are recent duplicates.
The extracellular domains of RAET1G and ULBP2 share 92%
amino acid identity, for example (4). In addition to their
sequence similarity, RAET1G and ULBP2 share similar expres-
sion patterns. Their transcripts are often coexpressed in cell
lines and are induced by the same stimuli (9, 10). Therefore, it
is striking that only two of the six ULBP/RAET1 proteins,
RAET1E and RAET1G, span the cell membrane.
The cell surface expression of NKG2D ligands is tightly con-
trolled and is regulated at multiple levels. First, the expression
of NKG2D ligand transcript is generally absent in healthy cells
but is up-regulated by cell stress signals such as viral infection
(11), Toll-like receptor signaling (9, 12), and DNA damage (13).
A second level of regulation has been proposed to act post-
transcriptionally,mediated bymicroRNAs (14). Third,NKG2D
ligand expression can be regulated at the post-translational
level. For example, Nice et al. (15) reported post-translational
regulation ofMult1 protein, which is considered as a functional
ortholog of RAET1G in mice. The protein undergoes ubiquiti-
nation on lysine residues in the cytoplasmic tail and consequent
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lysosomal degradation, preventing its surface expression. On
receipt of DNA damage signals, the ubiquitination of Mult1
protein was reduced, and the protein was stably expressed at
the cell surface (15). RAET1G has a single lysine residue in the
cytoplasmic tail, indicating that it is also a candidate for ubiq-
uitination-mediated regulation.
Here, we examined the trafficking and post-translational
modification of RAET1G in an effort to understand the role of
its largeC-terminal domain andhow itmight differ functionally
from other NKG2D ligands. To approach this, we set out to
clarify its mode of association with the cell membrane.
EXPERIMENTAL PROCEDURES
Cells and Plasmids—HT1080 and HeLa cells were grown in
Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum, 100 g/ml streptomycin, and 100 units/ml
penicillin. K562 cells were grown in RPMI 1640 medium con-
taining 10% fetal bovine serum and 100 g/ml streptomycin.
K562 class K cell lines were a kind gift from Dr. Kanzawa and
Prof. Kinoshita, Osaka University, Japan (16). The untagged,
epitope-tagged, and GFP fusion constructs of RAET1G for
transient transfection were created in the vector pcDNA3
(Invitrogen). Transient transfections were performed using
Lipofectamine 2000 (Invitrogen) following the manufacturer’s
protocol. Stable cell lines were created with a lentiviral expres-
sion system (gift from Prof. Paul Lehner, University of Cam-
bridge, UK) (17).
Antibodies andReagents—Polyclonal anti-RAET1G-tail anti-
serum was previously described (18). Polyclonal and mono-
clonal anti-ULBP2 (AF1298 forWestern blotting and immuno-
precipitation, MAb1298 for flow cytometry), anti-MICB
(AF1599 for Western blotting and immunoprecipitation,
MAb1599 for flow cytometry) antibodies were purchased from
R&D Systems. Anti-GFP antibody was from Abcam. Anti-V5
antibody (R960-25) was from Invitrogen. Isotype control
mouse antibody (X0943), anti-goat (P0449), andmouse (P0447)
Fc horseradish peroxidase-conjugated antibodies were pur-
chased from Dako UK Ltd. Isotype control Fab antibody
(MOR6391) and goat anti-human IgG F(ab)2 horseradish per-
oxidase-conjugated antibody (0500-0099) were from AbD
Serotec. Alexa Fluor 633 goat anti-mouse (A21053) and goat
anti-human (A21091) antibodies were fromMolecular Probes.
Preparation of Monoclonal Antibody—The monoclonal
recombinant anti-RAET1G antibody (anti-RAET1GmAb) was
generated by AbD Serotec, using the His-tagged extracellular
domain of RAET1G as antigen of interest andHis-tagged extra-
cellular domain of closely related ULBP2 for negative selection.
His-tagged extracellular domains of RAET1G and ULBP2 pro-
teins were constructed in the vector pMW-H6 (a gift from Dr.
A. Barrow), expressed in BL21 (DE3) pLysS competent cells
(also from Dr. A. Barrow), purified using nickel-nitrilotriacetic
acid-agarose (Qiagen) and refolded in 100 mM Tris-HCl (pH
8.0), 400 mM L-arginine hydrochloride, 2 mM EDTA, 5 mM
reduced glutathione, 0.5 mM oxidized glutathione, and 0.1 mM
PMSF, at 4 °C for 3 days. Each antibody had a 5-fold higher
signal on ELISA detection of 5g/ml RAET1G, compared with
ULBP2, when detected with 5 g/ml antibody.
Endo H and PNGase Treatment—Cells were directly lysed in
reducing SDS-PAGE sample buffer, boiled, and digested by
Endo H or PNGase (New England Biolabs) for 30 min at 37 °C
and subjected to Western blot analysis.
PI-PLC Treatment—Cells were washed with PBS and
stripped with 10 mM EDTA in PBS. After washing with PBS
twice, cells were incubated with 1 unit/ml PI-PLC (Sigma) in
PBS for 30min at 4 °C. The cells were washedwith ice-cold PBS
containing 1% bovine serum albumin and subjected to FACS
analysis or centrifuged with 13,000 rpm for 15 min at 4 °C, and
the resulting supernatant and pellet were subjected toWestern
blot analysis.
Western Blotting—Equal numbers of viable cells were lysed
into reducing SDS-PAGE sample buffer, boiled, and separated
by SDS-PAGE. Western blotting was performed using goat
anti-MICB (AF1599) or goat anti-ULBP2 (AF1298) antibody
(R&D Systems) or anti-RAET1G mAb described.
Pulse-Chase—Cells were harvested, washed in PBS, and then
starved for 1 h at 37 °C in methionine/cysteine-free RPMI 1640
medium (Sigma) supplemented with 2 mmol/liter glutamine,
5% dialyzed fetal calf serum, and 10 mmol/liter HEPES. Cells
were labeled with 1 mCi of [35S]methionine and [35S]cysteine
Pro-mix (Amersham Biosciences; GE Healthcare)/107 cells for
0–60 min at 37 °C. Cells were chased in culture medium sup-
plemented with excess unlabeled cysteine/methionine for
0–120 min, harvested, washed in ice-cold PBS, and then sub-
jected to immunoprecipitation.
Immunoprecipitation—Equal numbers of viable cells were
lysed in RIPA buffer (0.1% SDS, 0.5% DOC, 1% Nonidet P-40,
150mMNaCl, and 50mMTris-HCl (pH8.0)) containing protein
inhibitor mixture tablet (Roche Diagnostics) and 10 mM PMSF
for 30 min at 4 °C, and the resulting supernatant was incubated
with antibody described and protein G-Sepharose 4B (GE
Healthcare) with incubation overnight at 4 °C. After the beads
were washed five times with RIPA buffer, proteins were eluted
with SDS sample buffer by boiling for 5 min. Total protein and
isolated labeled proteins were analyzed by Western blotting.
Flow Cytometry—Cells were washed with PBS and stripped
off in 10 mM EDTA in PBS. After washing in ice-cold PBS con-
taining 1% bovine serum albumin, cells were stained with
mouse anti-ULBP2 (MAb1298), mouse anti-MICB (MAb1599)
(R&D Systems) or anti-RAET1G antibody for 1 h at 4 °C, fol-
lowed by goat anti-mouse Alexa Fluor 633 conjugate (A21053;
Molecular Probes). As the stable cell lines were roughly 70%
GFP-positive, GFP-negative cells were gated out in analysis.
Data were then collected using BD FACSCalibur. All experi-
ments were repeated at least twice.
Site-directed Mutagenesis—Mutation of RAET1G was gen-
erated by oligonucleotide-directed mutagenesis using prim-
ers 5-CACCCACCATGCCCTCAGGCAC-3 and 5-GTG-
CTCCTGCACTTGGCTCC-3 and KOD DNA polymerase
(Novagen).
Cell Surface Immunoprecipitation—For cell surface immu-
noprecipitation, the cells werewashed three timeswith ice-cold
PBS then incubated for 1 h with anti-RAET1GmAb in ice-cold
PBS. Afterwashing three timeswith ice-cold PBS, the cells were
lysed in RIPAbuffer containing protein inhibitormixture tablet
(Roche Diagnostics) and 10mM PMSF, and the resulting super-
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natant was incubated with anti-V5 agarose (A7345; Sigma)
overnight at 4 °C. After the beads were washed five times with
RIPA buffer, bound proteins were eluted with SDS sample
buffer by boiling for 5 min. Total protein and isolated labeled
proteins were analyzed by Western blotting. The experiments
were independently repeated twice.
RESULTS
Detection of RAET1G Protein with Antibodies against the
Extracellular and Cytoplasmic Domains—We compared
expression patterns of RAET1G onWestern blots of bothHeLa
and HT1080 cell lines using untagged, recombinant RAET1G,
with three different reagents for detection. Reagent 1 was poly-
clonal anti-RAET1G-tail antiserum, which was raised using
peptides corresponding to part of the cytoplasmic tail (18). Rea-
gent 2 was anti-ULBP2 antibody, which recognizes both
RAET1G and ULBP2, because their extracellular domains are
almost identical to each other (18). Reagent 3 is an antibody
specific to the extracellular portion of RAET1G (anti-RAET1G
mAb), as described below.
The anti-RAET1G-tail antiserum detected bands of 37
kDa, corresponding to the predicted molecular mass of
RAET1G (Fig. 1A). Anti-ULBP2 antibody detected two addi-
tional bands of 28 and 32 kDa (Fig. 1B). No bands were
detected in lysates of untransfected cells.
To avoid any cross-reaction with
endogenous NKG2D ligands, such as
ULBP2 and RAET1L, we made spe-
cific monoclonal recombinant anti-
body against the RAET1G using
phage display technology. Bacterially
expressed recombinantRAET1Gand
ULBP protein were produced as anti-
gens. We screened for positive bind-
ing to RAET1Gwhile eliminating any
antibodies that bound recombinant
ULBP2 in a negative selection step. In
Western blot and FACS analysis this
anti-RAET1G antibody specifically
recognized recombinant RAET1G
protein transfected into Chinese hamster ovary cells, but not
ULBP2 or RAET1L (supplemental Fig. S1). Using this RAET1G-
specific reagent, we confirmed RAET1G expression in the trans-
fected HeLa and HT1080 cell lines. The antibody clearly detected
bands of 28 and 32 kDa, in patterns that were similar to
those detected by anti-ULBP2 antibody (Fig. 1C).
Cleavage of RAET1G Protein Occurs Soon after Protein
Synthesis—To characterize the RAET1Gbands further, we per-
formed pulse-chase experiments. Samples from cells trans-
duced with RAET1G or ULBP2 were pulsed for 20 min and
chased for 0–120 min before the proteins were immunopre-
cipitated. In the cells transduced with RAET1G, a 37 kDa
band, corresponding to the full-length protein, appeared from
the beginning of the 0-min chase and disappeared in 60 min
(Fig. 2A). Another band of 28 kDa was also detected at the
0-min chase, and a further one of 32 kDa appeared after a
60-min chase. In the cells transduced with ULBP2, an initial
band became weaker after 10 min, corresponding to the
appearance of a higher band, consistent with modification of
the ULBP2 protein (Fig. 2B).
To follow the timing of the RAET1G band of28 kDa more
closely, a shorter pulse time was applied, this time without
chase. The 37 kDa band appeared from the beginning of the
pulse, and the28 kDa band appeared later and became grad-
ually more intense (Fig. 2C).
These data suggest that the 28 kDa RAET1G band is
derived from cleavage of the37 kDa band and that the cleav-
age occurs soon after protein synthesis. They also suggest that
the32 kDa bandmight be derived frommodification of the 28
kDa band.
C terminus of RAET1G Protein Is Cleaved—To confirm the
pulse-chase results, we made epitope-tagged RAET1G con-
structs. RAET1G proteins were fused downstream of a generic
ER leader sequence and a FLAG tag, or upstream of a FLAG, or
enhanced GFP, tag (Fig. 3A). Anti-ULBP2 antibody, which rec-
ognizes the extracellular domain of RAET1G, detected 37
kDa bands in the lane containing untagged protein and slightly
higher bands in lanes with the N-terminal and C-terminal
FLAG-tagged RAET1G. A much higher band was observed in
the C-terminal GFP-tagged lane (Fig. 3B). These data con-
firmed expression of full-length RAET1G with its cytoplasmic
tail. In addition to bands representing the full-length proteins,
bands of 28 and 32 kDa were detected in lanes containing
FIGURE 1. Expressionpattern of RAET1Gprotein. Lysates of HeLa andHT1080 cells transfectedwith RAET1G
were subjected to SDS-PAGE (15% gel) separation and Western blotting with polyclonal anti-RAET1G-tail
antiserum raised with peptides corresponding to part of the cytoplasmic tail of the protein (A), polyclonal
anti-ULBP2 antibody (AF1298), (B) or monoclonal recombinant anti-RAET1G antibody generated using the
extracellular domain of the protein (anti-RAET1G mAb) (C). The band in untransfected HT1080 cells (C) is
nonspecific. The anti-RAET1GmAbdetected thedoublet bandonlyweakly inHT1080. The reason for this is not
clear. It may be partly due to conversion of the high molecular mass form to smaller products (as in B, right
panel, for example). The intensity of the nonspecific band makes longer exposure of these blots unfeasible.
FIGURE 2.Time course of the cleavageof RAET1Gprotein.A and B, HT1080
cells transduced with RAET1G (A) or ULBP2 (B) were pulse-labeled for 20 min
and chased for 0–120 min, followed by immunoprecipitation of RAET1G or
ULBP2with polyclonal anti-ULBP2 antibody (AF1298) and electrophoresis on
15% acrylamide gels. C, HT1080 cells were transduced with RAET1G pulse-
labeled for 0–60min, followed by immunoprecipitation of RAET1G and elec-
trophoresis on 15% acrylamide gels.
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untagged RAET1G, the C-terminal FLAG-tagged RAET1G,
and the C-terminal enhanced GFP-tagged molecule. Slightly
higher bands were seen in the lane with an N-terminal FLAG
tag, suggesting that the C terminus of RAET1G might be
cleaved.
With the anti-GFP antibody, in addition to the higher band
corresponding to full-length RAET1G-GFP, a band of27 kDa
was observed, corresponding to the molecular mass of GFP
(Fig. 3C). This supports the idea that the C terminus of
RAET1G protein is removed. Similar results were obtained
with the other cell lines, including HeLa, MelJuSo, and HCA7
(data not shown).
Transport of RAET1G after Cleavage—To determine the
intracellular localization of the four forms of RAET1G, lysates
of cells transduced with RAET1G were treated with two glyco-
sidases, Endo H and PNGase F, and protein was detected by
Western blotting (Fig. 4, A and B). Endo H does not cleave
processed N-linked sugars, but PNGase F does, so differential
sensitivity to these two glycosidases can be interpreted to estab-
lish transit to the Golgi. The upper band of 37 kDa and the
lower band of 28 kDa were sensitive to both Endo H and
PNGase F, suggesting that they were glycosylated but remained
in the ER. The lower band of the37 kDa doublet was resistant
to both Endo H and PNGase F, indicating that this is immature
protein. The32 kDa band was resistant to Endo H but sensi-
tive to PNGase F, suggesting that this form might be glycosy-
lated and transported, at least to the Golgi. These data are con-
sistent with modification of the RAET1G protein in the Golgi
after cleavage of its C-terminal region.
Cell surface immunoprecipitation was performed to deter-
mine which forms of the protein are expressed in this location.
Cells transduced with RAET1G were stained with anti-
RAET1G antibody (anti-RAET1G mAb), and the bound cell
surface proteins were immunoprecipitated and detected in
Western blots. Only the32 kDa band was clearly detected in
the eluate sample (Fig. 4C), suggesting that this form is trans-
ported to the cell surface after modification in the Golgi.
GPI Anchoring of RAET1G—Only RAET1E and RAET1G
have been reported as transmembrane proteins, among the
ULBP family proteins, although ULBP2 and RAET1L share
high similarity to RAET1G. We checked for GPI-anchoring
motifs in RAET1Gusing website software, PredGPI. It was sug-
gested, with only 17% probability, that RAET1G was GPI-an-
chored. Previous reports of mutational analysis of the C-termi-
nal GPI signal sequences of several proteins have demonstrated
that the length of the hydrophobic region and the spacer
sequence between the GPI-anchoring site and the hydrophobic
region are important for GPI anchoring (19), and we found that
these features were conserved in RAET1G, ULBP2, and
RAET1L. Because we established that RAET1G protein is
cleaved at its C terminus, we examined sequences of the prod-
ucts of protein cleavage. In this case, PredGPI indicated with
100% probability that RAET1G protein is GPI-anchored by a
serine residue (Ser216) that is conserved among the three
proteins.
PI-PLC Treatment Released RAET1G Protein—To test
experimentally whether RAET1G protein is GPI-anchored,
three experiments were performed. First, we checked byWest-
ern blotting whether the protein is released by PI-PLC treat-
ment. GPI-anchored protein ULBP2 was used as a positive
control and transmembrane-associated MICB as a negative
FIGURE 3. Cleavage of cytoplasmic tail of RAET1G protein. A, schematic
representation of epitope-tagged RAET1G constructs is shown. RAET1G was
cloned downstream of a generic ER leader sequence and a FLAG tag,
upstream of a FLAG tag or GFP. B and C, lysates of HT1080 cells transduced
with RAET1G or epitope-tagged RAET1G were collected and subjected to
SDS-PAGE (15% gel) separation and Western blotting with polyclonal anti-
ULBP2 antibody (AF1298) (B) or with anti-GFP antibody (C). Lane 1, untrans-
fected; lane 2, transfected with untagged; lane 3, with N-terminal FLAG-
tagged; lane 4, transfected with C-terminal FLAG-tagged; and lane 5,
transfected with C-terminal GFP-tagged RAET1G.
FIGURE 4. Cellular localization of each form of RAET1G protein. A and B,
lysates of HT1080 and HeLa cells transfected with RAET1G were digested by
EndoH (A) or PNGase (B) and subjected toSDS-PAGE (15%gel) separationand
Western blotting with polyclonal anti-ULBP2 antibody (AF1298). C, HT1080
cells transduced with RAET1G were surface-stained with monoclonal anti-
RAET1G antibody (anti-RAET1GmAb) and after washing, the surface proteins
were lysed, immunoprecipitated, and subjected to SDS-PAGE (15% gel) sep-
aration and Western blotting with polyclonal anti-ULBP2 antibody (AF1298).
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control. A band of released RAET1G protein was detected in
the supernatant of only PI-PLC-treated cells, which suggests
that at least someRAET1G isGPI-anchored (Fig. 5A). AULBP2
bandwas also seen, but no band forMICB, in the supernatant of
PI-PLC treated cells. Similar data were obtained for HeLa cells
(not shown).
To confirm these findings, expression on the surface of cells
was examined in FACS. Surface expression of RAET1G was
reduced slightly after PI-PLC treatment (Fig. 5B). The surface
expression of ULBP2 was dramatically reduced, but PI-PLC
treatment did not affect the surface level ofMICB. These exper-
iments show that at least some RAET1G is GPI-linked to the
cell surface. The slight reduction in cell surface expression of
RAET1G is in contrast to the other data (e.g. Fig. 6C), which
indicate that a substantial fraction of the molecules are GPI-
anchored. The reason for this discrepancy is not known. The
apparent small shift after PI-PLC treatment for RAET1G may
relate to its low initial level on the cell surface. Alternatively,
RAET1Gmay be a poor substrate for PI-PLC at the cell surface.
Reduced Surface Expression of RAET1G inGPI-negative Cells—
As an alternative way of examining GPI anchoring of RAET1G,
we monitored expression of the protein in a GPI biosynthetic
mutant. We chose a K562 cell line, K562 class K, which has
defects in one of the major enzymes of GPI biosynthesis, GPI
amidase (16). Three bandswere detected of28 kDa,32 kDa,
and37 kDa in normal, GPI-positive, K562 cells. The28 kDa
and32 kDa bands disappeared in the GPI-negative cells, and
the intensity of the 37 kDa band increased (Fig. 6A). The upper
band of ULBP2, corresponding to the GPI-anchored form, was
detected in GPI-positive cells but not in GPI-negative cells. No
difference inMICB expression was detected between GPI-pos-
itive and GPI-negative cells, although total band intensity was
changed. Furthermore, the surface expression of RAET1G was
dramatically reduced in the GPI-negative, compared with the
normal GPI-positive, cells (Fig. 6B). The surface expression of
ULBP2 was also reduced in GPI-negative cells, but MICB
FIGURE 5.RAET1Gprotein is releasedbyPI-PLC treatment.A, HT1080 cells
transduced with RAET1G, ULBP2, and MICB were treated with PI-PLC and
centrifuged. Supernatant and pellet were collected for SDS-PAGE (15% gel)
separation and Western blotting with polyclonal anti-ULBP2 (AF1298) and
anti-MICB (AF1599) antibody. B–D, HT1080 cells transduced with RAET1G (B),
ULBP2 (C), and MICB (D) were treated with PI-PLC and washed with PBS, and
the level of surface RAET1G was assessed by FACS using monoclonal anti-
RAET1G (anti-RAET1G mAb), anti-ULBP2 (MAb1298), and anti-MICB
(MAb1599) antibody in the FL4 channel. Shaded area and black dashed lines
represent isotype controls.
FIGURE 6. RAET1G expression in GPI-biosynthetic mutant cells. A, lysates
of K562 and K562 class K cell lines transduced with RAET1G, ULBP2, or MICB
were subjected to SDS-PAGE (15% gel) separation andWestern blotting with
polyclonal anti-ULBP2 (AF1298) or anti-MICB (AF1599) antibody. B–G, surface
expression level of RAET1G (B and C), ULBP2 (D and E), or MICB (F and G) in
K562 (B, D, and F) and K562 class K (C, E, and G) cell lines transduced with
RAET1G, ULBP2, or MICB were assessed by FACS using monoclonal anti-
RAET1G (anti-RAET1GmAb), anti-ULBP2 (MAb1298), or anti-MICB (MAb1599)
antibody in the FL4 channel. Shaded area and dashed line represent isotype
controls in untransfected and transduced cells, respectively. Solid black line
and bold black line represent each antibody staining in untransfected and
transduced cells, respectively.
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expression on the cell surfacewas high in bothGPI-positive and
GPI-negative cells.
GPI Anchoring of RAET1G Protein—To determine whether
RAET1G is directlyGPI-anchored,wemutatedGPI anchor res-
idues in the molecule. PredGPI indicated that Ser216 in both
ULBP2 and RAET1L is a  site, meaning that it is the residue
most likely to be directly associated with GPI anchor. In addi-
tion to Ser216, the adjacent two residues are conserved among
RAET1G, ULBP2, and RAET1L as these sequences all have
Ser217 in the 1 site and Gly218 in the 2 site (Fig. 7A). We
made RAET1G protein in which the serine residue in the  site
was exchanged for a proline, a residue that has never been
reported to be used as a site (20). InWestern blots, the inten-
sity of the28 kDa and32 kDa bands decreased, although the
intensity of the 37 kDa bands did not change (Fig. 7B). In
addition, surface expression by FACS of RAET1G protein,
mutated in the GPI anchor, was lower than that of normal
RAET1G (Fig. 7C). Similar results were obtained in HeLa cells
(data not shown).
DISCUSSION
NKG2D ligands are critical activators of NK cells and subsets
of T cells. Their variation in different species suggests that they
are under selection driven by immune evasion. Mice have at
least six different NKG2D ligands, some of which are trans-
membrane molecules and the others GPI-anchored (5, 6). Sim-
ilarly, human MIC proteins, which are not present in mouse,
span themembrane, but ULBP1–3 depend on GPI attachment.
RAET1G is predicted to span the cell membrane and to contain
a long cytoplasmic tail. We now show that the arrangement of
this molecule is more complex and that it undergoes post-
translational cleavage and modification before being trans-
ported to the cell surface.
Our data suggest that RAET1G undergoes GPI anchoring, in
line with most of the other ULBP family proteins, and the32
kDa band corresponds to the functional GPI-anchored form
(supplemental Fig. 2). The immediate appearance of the 37
kDa band and its subsequent replacement by28 kDa and32
kDa bands in the pulse-chase suggest that RAET1G might be
first translated as the full-length form and then cleaved just
after protein synthesis. The data using epitope-taggedRAET1G
called for cleavage of the C terminus of the protein. The disap-
pearance of both 28 kDa and 32 kDa bands in Western
blots, using a GPI-anchoring mutant defective in GPI-trans-
amidase, suggests that the cleavage and GPI anchoring might
occur simultaneously by the enzyme located in the ER. The
pulse-chase data showing that the 32 kDa band appeared
after the28 kDa band, coupled with its resistance of Endo H
digestion, suggest that the 32 kDa GPI-anchored RAET1G
formmight be transported to the Golgi, where it could bemod-
ified further. The FACS data showing the reduced cell surface
expression of RAET1G in the GPI-anchoring mutant cell line
support the data. Furthermore, the cell surface immunopre-
cipitation data suggest that this form might be transported to
the cell surface.
The extracellular domain of RAET1G protein shares high
similarity with those domains of ULBP2 and RAET1L pro-
teins. It has been reported that RAET1G and ULBP2 tran-
scripts are generally coexpressed in different cell lines and
tissues (9, 10). The long cytoplasmic tail is a specific feature
of the RAET1G protein. However, we showed here that the
cytoplasmic tail of RAET1G is cleaved and that at least a
proportion of the protein works as a GPI-anchored protein.
What then is the functional difference between RAET1G and
ULBP2? One hypothesis is that their expression might be
regulated differently. RAET1G might mainly use post-trans-
lational regulation to respond to stimuli rapidly, whereas
ULBP2 could mainly use transcriptional regulation. Indeed,
the mode of expression of RAET1G at the cell surface might
be regulated by transport from the ER to the Golgi or by
modification in the Golgi. This arrangement could reflect
the need to express this NKG2D ligand rapidly at the surface
of the cell in response to infection. Most RAET1G protein
might reside inside the cell in normal conditions, and envi-
ronmental stimuli such as viral infection might trigger
release to the cell surface. This hypothesis could explain the
reason for the lower expression of RAET1G on the cell surface
compared with ULBP2 and MICB. The slower glycosylation of
RAET1G, compared with ULBP2, in our pulse-chase data is
consistent with this. Further investigation is needed to examine
what kind of environmental stimuli might regulate the cell sur-
face expression of RAET1G post-translationally.
FIGURE 7. Expression of RAET1G mutated in predicted GPI-anchoring
position. A, amino acid alignment of RAET1G, ULBP2, and RAET1L proteins
around the predicted GPI-anchoring position is shown. Conserved residues
are shown in bold. B, lysates of HT1080 cells transfected with wild-type
RAET1G (RAET1G) and RAET1Gmutated inGPI-anchoring position (mRAET1G)
were subjected to SDS-PAGE (15% gel) separation andWestern blotting with
polyclonal anti-ULBP2 antibody (AF1298). C, HT1080 cells transduced with
wild-type RAET1G (RAET1G) and RAET1G mutated in GPI-anchoring position
(mRAET1G) were assessed by FACS using anti-RAET1G mAb in FL4 channel.
Shaded area and black and gray dashed lines represent isotype controls.
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An alternative hypothesis is that RAET1G functions as a
decoy in viral infection. RAET1G protein interacts weakly with
NKG2D compared with ULBP2 (7, 10). RAET1G proteinmight
sequester viral proteins that target ULBP2, for example,
although it binds UL-16 very weakly if at all. It is also possible
that NKG2D is not the primary receptor for RAET1G and that
it serves as a ligand for other immunoreceptor molecules.
It has been reported that the cytoplasmic tail of Mult1 pro-
tein, which is proposed to be a functional ortholog of RAET1G
in mice, undergoes ubiquitination-mediated regulation (15).
However, on activation of cellular stress pathways by DNA-
damaging agents the ubiquitin-mediated turnover ofMult1was
reduced, and the protein was expressed at the cell surface.
RAET1G has been considered to a candidate to be regulated by
similar mechanism (15), although our data suggest that the C
terminus of RAET1G is proteolytically cleaved. A question
arises concerning the function of the cytoplasmic tail of
RAET1G. The tail does not share any motif or similarity to
other proteins, although its transmembrane and hydrophobic
regions were similar to those of the other ULBPs (supple-
mental Fig. S3). There is no splice junction in the vicinity, indi-
cating that the cytoplasmic tail of RAET1G might have been
derived by duplication ofULBP2, followedby a frameshift in the
hydrophobic region.
Our experiments all suggest that RAET1G protein under-
goes GPI anchoring, like most other ULBP/RAET1 family pro-
teins. However, the antiserum against the cytoplasmic tail
detected protein in some tissue, including cancer cells (18).One
interpretation of all the data is that RAET1G protein might
exist as both isoforms, GPI-anchored and transmembrane.
Slight reduction of cell surface expression of RAET1G by PI-
PLC treatment is consistent with this hypothesis. In fact, the
ratio between the prospective transmembrane form (37 kDa
band) and the GPI-anchored form (32 kDa band) varies
depending on cell types and conditions (data not shown).
Therefore, it is possible that the cleavage and processing of
RAET1G could be altered on receipt of cellular stress signals.
There are other reports of two isoforms of some proteins regu-
lated post-transcriptionally (21). Expression of both transmem-
brane and GPI-linked forms of NKG2D ligands could be a host
strategy to evade subversion by viruses as two alternative cou-
plingmechanisms would bemore difficult to target. It might be
a feature of other NKG2D ligands that has not been explored
in detail yet. Although we detected the tail of RAET1G in
tissue staining, our experiments would not distinguish
whether the tail was attached to the surface protein. The
antiserum could also recognize the C-terminal cleavage
product in the cytoplasm.
In vivo expression of RAET1Ghas been difficult to followdue
to the lack of specific antibody. Because of the high similarity of
the extracellular domain to ULBP2 and RAET1L, antiserum
against the cytoplasmic tail (anti-RAET1G-tail antiserum) was
used previously to detect the protein (18). However, our data in
this paper suggest that the antiserummight not be able to trace
the entire expression of all RAET1G protein because of cleav-
age of the cytoplasmic tail. Specific anti-RAET1G antibody will
be crucial to analyze the function of this protein in vivo. We
attempted to detect endogenous expression of the protein in
several nontransfected cell lines using the recombinant mono-
clonal antibody (anti-RAET1G mAb), but no significant pro-
tein expression was observed by Western blotting or FACS in
cell lines expressing RAET1G transcripts (data not shown).
Levels of protein expression of RAET1G in the cell lines might
not be sufficient to be detected by the antibody in Western
blotting or FACS, and expression might only be increased on
receipt of certain signals, such as viral infection or DNA dam-
age. There are other reports demonstrating that different cells
and tissues express NKG2D ligand transcripts but lack corre-
sponding protein expression (22–26). Clearly, NKG2D ligand
expression is subject to complex regulation at several levels:
the transcriptional level, the post-transcriptional level by
microRNAs (14), and at post-translational level, for example
the processing of RAET1G as we have reported here and the
S-acylation ofMICA (27). It is also clear that thesemechanisms
vary between NKG2D ligands and may vary between cell types,
presenting a considerable challenge to understand the NKG2D
immune recognition system fully.
Expression of RAET1G and RAET1E is subject to alternative
splicing to produce soluble proteins (8, 18, 28, 29), and soluble
ULBP2 is released bymetalloprotease in tumor cells (30). It will
be interesting to examine whether soluble forms of RAET1G
are detected by anti-RAET1G antibody in ELISAs. This issue
needs further investigation, using other cell lines, tissues, and
conditions to analyze the protein in vivo. It will also be crucial to
assess whether RAET1G trafficking and post-translational
processing is altered in specific cell types or when cells are sub-
jected to stress such as viral infection or DNA damage.
RAET1G expression has been detected in gut epithelial cell lay-
ers (8, 18). These cells are highly specialized and form polarized
cell layers allowing interfacewith the gut lumen on one side and
lymphocytes on the other. MICA has been shown to have spe-
cific trafficking properties in these cell types (31), and it will be
interesting to assess RAET1G trafficking and modification in
this cell type.
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